Efficacy and safety of a high purity, double virus inactivated factor VIII/von Willebrand factor concentrate (Biostate®) in patients with von Willebrand disorder requiring invasive or surgical procedures

Haemophilia

Volumn 13, Issue 2, 2007, Pages 144-148

  Shortt, J ^a   Dunkley, S ^b   Rickard, K ^b   Baker, R ^c,d   Street, A ^a  

^a ALFRED HOSPITAL   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Factor replacement; Factor VIII von Willebrand factor concentrate; Invasive procedures; Surgery; Von Willebrand disorder

Indexed keywords

BIOSTATE; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; AUSTRALIA; BLEEDING; BOLUS INJECTION; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG PURITY; DRUG SAFETY; FEMALE; HEMOSTASIS; HUMAN; INVASIVE PROCEDURE; MALE; MEDICAL RECORD REVIEW; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SUBSTITUTION THERAPY; SURGICAL TECHNIQUE; TREATMENT RESPONSE; VIRUS INACTIVATION; VON WILLEBRAND DISEASE;

AGED; COAGULANTS; FEMALE; HEMOSTASIS, SURGICAL; HUMANS; INTRAOPERATIVE CARE; MALE; MIDDLE AGED; POSTOPERATIVE HEMORRHAGE; TREATMENT OUTCOME; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 33846903642     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01430.x     Document Type: Article

References (11)

1. Federici AB, Mannucci PM. Diagnosis and management of von Willebrand disease. Haemophilia 1999; 5 (suppl. 2): 28-37.
2. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998; 67: 395-424.
3. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: The first 20years. Blood 1997; 90: 2515-21.
4. Mannucci PM. How I treat patients with von Willebrand disease. Blood 2001; 97: 1915-9.
5. Rodeghiero F, Castaman G, Meyer D, Mannucci PM. Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease. Vox Sang 1992; 62: 193-9.
6. Ong YL, Hull DR, Mayne EE. Menorrhagia in von Willebrand disease successfully treated with single daily dose tranexamic acid. Haemophilia 1998; 4: 63-5.
7. Favaloro EJ, Bukuya M, Martinelli T et al. A comparative multi-laboratory assessment of three factor VIII/von Willebrand factor concentrates. Thromb Haemost 2002; 87: 466-76.
8. Favaloro EJ, Lloyd J, Rowell J et al. A cross-over, multi-centre study to compare the pharmacokinetics of two factor concentrates (Biostate® and AHF (High Purity)) in people with von Willebrand disorder. Haemophilia 2004; 10 (suppl. 3): 8.
9. Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994; 71: 520-5.
10. Federici AB, Morfini M, Castman G et al. Multicentre retrospective survey on efficacy and safety of Haemate-P® in a large cohort of Italian patients with von Willebrand disease. Haemophilia 2006; 12 (suppl. 2): 138.
11. Gill JC, Leissinger C, Di Paola J et al. Von Willebrand Factor/Factor VIII concentrate (Humate-P®) for surgical prophylaxis of excessive bleeding in patients with severe von Willebrand disease (VWD). Haemophilia 2006; 12 (suppl. 2): 138.